This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
by Zacks Equity Research
Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.
BMYPositive Net Change PBYINegative Net Change VNDANegative Net Change
biotechs earnings
Why Apellis (APLS) Might Surprise This Earnings Season
by Zacks Equity Research
Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
APLSPositive Net Change
biotechnology biotechs medical
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.
ACETPositive Net Change PBYINegative Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Moderna (MRNA) Beats on Q4 Earnings & Sales, Reiterates View
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
MRKNegative Net Change MRNAPositive Net Change ACETPositive Net Change PBYINegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates
by Zacks Equity Research
Earnings from Moderna (MRNA) and pipeline update from RAPT are in focus in the biotech sector.
REGNPositive Net Change MRNAPositive Net Change SRPTNegative Net Change IOVANegative Net Change RAPTPositive Net Change
biotechnology biotechs pharmaceuticals
Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y
by Zacks Equity Research
Repligen's (RGEN) fourth-quarter 2023 earnings miss estimates and decline year over year. Stock declines.
RGENNegative Net Change PBYINegative Net Change VNDANegative Net Change
biotechs earnings
CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up
by Zacks Equity Research
CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.
VRTXPositive Net Change PBYINegative Net Change ADMAPositive Net Change CRSPNegative Net Change
biotechnology biotechs cell-therapy crispr dna-sequencing earnings gene-editing gene-therapy medical pharmaceuticals
5 Stocks Likely to Gain on Q4 Earnings Today After Market Close
by Nalak Das
We have narrowed our search to five large-cap stocks that are poised to beat on earnings today after market closes. These are: BKNG, AMH, FND, BMRN, PBA.
BMRNPositive Net Change PBAPositive Net Change AMHPositive Net Change FNDPositive Net Change BKNGNegative Net Change
biotechs construction internet-content oil-energy reit
Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag
by Zacks Equity Research
Halozyme's (HALO) fourth-quarter 2023 earnings meet estimates, while revenues miss the same.
RHHBYPositive Net Change JNJPositive Net Change HALOPositive Net Change EXASPositive Net Change
biotechs earnings
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.
RHHBYPositive Net Change SRPTNegative Net Change ARQTNegative Net Change CGEMPositive Net Change
biotechs gene-therapy medical pharmaceuticals
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
by Zacks Equity Research
Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.
JAZZNegative Net Change PBYINegative Net Change EXASPositive Net Change AXSMPositive Net Change
biotechs earnings
Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Investor focus is likely to be on Aquestive Therapeutics' (AQST) updates regarding key pipeline candidate, Anaphylm Sublingual Film, on the fourth-quarter 2023 earnings call.
MRNAPositive Net Change SRPTNegative Net Change AMRNNegative Net Change AQSTPositive Net Change
biotechs
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
by Ekta Bagri
Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
BMRNPositive Net Change MRNAPositive Net Change NTLAPositive Net Change BHCPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review
by Zacks Equity Research
Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.
BMYPositive Net Change ACETPositive Net Change PBYINegative Net Change ADMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Amphastar's (AMPH) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its pharmaceutical products.
AMPHPositive Net Change MRNAPositive Net Change SRPTNegative Net Change CRSPNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.
AMGNNegative Net Change SRPTNegative Net Change BGNEPositive Net Change CRSPNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
by Zacks Equity Research
The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.
PFEPositive Net Change PBYINegative Net Change ADMAPositive Net Change ACIUNegative Net Change
biotechs pharmaceuticals
Roche's (RHHBY) Xolair Gets Approval for Food Allergies
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.
REGNPositive Net Change NVSPositive Net Change RHHBYPositive Net Change PBYINegative Net Change
biotechnology biotechs pharmaceuticals
Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.
MRKNegative Net Change MRNAPositive Net Change ARQTNegative Net Change CGEMPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi
by Zacks Equity Research
The FDA grants accelerated approval to Iovance's (IOVA) Amtagvi (lifileucel) for treating advanced melanoma after anti-PD-1 and targeted therapy. Stock rises.
PBYINegative Net Change EXASPositive Net Change IOVANegative Net Change
biotechs
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
by Zacks Equity Research
Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.
RHHBYPositive Net Change SRPTNegative Net Change ADMAPositive Net Change IMCRPositive Net Change
biotechnology biotechs cell-therapy gene-editing gene-therapy medical pharmaceuticals
Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.
RHHBYPositive Net Change BMYPositive Net Change NVOPositive Net Change PRTAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow
by Zacks Equity Research
Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
MRKNegative Net Change SRPTNegative Net Change CORTPositive Net Change PBYINegative Net Change
biotechnology biotechs earnings pharmaceuticals
Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%
by Zacks Equity Research
Alnylam (ALNY) reports mixed fourth-quarter 2023 results, as earnings beat estimates, while revenues miss the same. The stock of the company falls 10%.
REGNPositive Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season
by Zacks Equity Research
Orchestra BioMed (OBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
OBIONegative Net Change
biotechs medical